Insulin Degludec
Insulin degludec
Tresiba
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Common uses
Type 1 diabetes mellitus0, Type 2 diabetes basal coverage0
Pharmacy
Starting dose
~10 units SC at the same time daily, or 0.1-0.2 units/kg/d; titrate by fasting glucose
Preparations
100 U/mL (FlexTouch pen) and 200 U/mL (FlexTouch pen, higher-dose convenience)
US FDA Max
Titrated to glucose; no fixed ceiling
Pharmacology
Routes
Subcutaneous (never IV; not for use in insulin pumps)
Onset
~1 hour
Duration
>42 hours per dose (effectively flat once at steady state)
Half-life
~25 hours apparent (functional duration well over 42 hours from multi-hexamer depot)[1]
Bioavailability
~100% from subcutaneous depot
Pregnancy
Insulin is the preferred glucose-lowering therapy in pregnancy; degludec has reassuring observational data.[citation needed]
Legal status
Rx-only in US
Purported mechanism
Insulin degludec self-assembles after subcutaneous injection into long multi-hexamer chains that slowly dissociate into monomers, providing a flat ultra-long-duration insulin profile (>42 hours) that supports forgiving dose-timing windows and lower nocturnal hypoglycemia rates than glargine in DEVOTE and SWITCH trials.0 Binds the same insulin receptor as endogenous insulin with comparable mitogenic-to-metabolic ratio[1].
References
- ↑ 1.0 1.1 FDA Prescribing Information, Tresiba (insulin degludec), Novo Nordisk, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203314s022lbl.pdf